Whalesbook
UBS Adjusts Indian Mid-Cap Ratings
UBS's latest adjustments to Indian mid-cap company ratings reveal a complex market. For Astral, the focus is on improved margins from price changes and growth. Bharat Forge presents a mixed picture, with strong defense orders facing challenges from industrial segment pressures and high valuations. Meanwhile, Angel One and Bandhan Bank are navigating their unique sector challenges, with UBS taking a measured view.
Astral Benefits from PVC Price Hikes
UBS expects Astral's 'Buy' rating to hold, driven by recent PVC price increases of about ₹12 per kg in March, which should improve earnings and profit margins. Astral is adding capacity at its Kanpur and Hyderabad plants to gain market share. The company also anticipates its UK adhesive business will see normalized profit margins within the next year. This positive outlook aligns with a chemical sector expected to grow strongly, with specialty chemicals predicted to expand at an annual rate of 10-12%. Astral has a market capitalization of ₹66,500 crore and a trailing 12-month P/E ratio of 58.15, showing it trades at a premium valuation.
Bharat Forge Faces Valuation Concerns
UBS maintains a 'Sell' rating on Bharat Forge, with a target price of ₹1,365. This call comes despite the company forecasting 12-14% annual revenue growth for the next three to four years. Analysts note potential risks from defense order delays, though Bharat Forge aims to double its aerospace revenue to about ₹7 billion in two to three years. The company has a market capitalization of ₹90,800 crore and a P/E ratio of 9.51. UBS has cited valuation concerns, noting it is one standard deviation above Bharat Forge's 10-year average, and global uncertainty impacting its domestic and export businesses outside defense. While India's industrial production increased 4.8% in January 2026, Bharat Forge's core automotive and industrial segments are cyclical and contrast with defense sector optimism.
Angel One Navigates Competition
UBS rates Angel One 'Neutral' with a ₹2,900 target price. UBS highlighted management's confidence in maintaining market share in brokerage services, pointing to regulations that deter new competitors. Angel One uses data analytics for customer growth and cross-selling, and is expanding into mutual funds and credit. It is a leading firm in new systematic investment plan (SIP) flows. The company has a market capitalization of ₹19,959 crore and a P/E of 23.44. However, competition is increasing, with rivals like Groww showing better profit margins and higher customer asset values, even though Angel One leads in revenue size. Angel One's revenue grew 9.2% over the last four quarters.
Bandhan Bank Focuses on Credit Costs
UBS maintains its 'Neutral' rating for Bandhan Bank, setting a target price of ₹220. Management has confirmed its expected credit loss guidance of 1.6-1.7% by fiscal year 2027. The bank noted improvements in loan defaults quarter-over-quarter and anticipates little operational effect from the West Bengal election and the Bihar microfinance bill. Bandhan Bank has a market capitalization of ₹29,472 crore and a P/E of 29.26. Moody's Ratings expects India's banking sector to remain stable, with low bad loans thanks to strong economic growth. The sector's return on assets is projected to increase to 1.2-1.3% in fiscal years 2026-27. Despite these positive industry trends, Bandhan Bank faces difficulties in attracting deposits in a highly competitive market.
Growth Outlook for Kaynes Technology and Quality Power
Kaynes Technology India aims for $1 billion in revenue by fiscal year 2028, supported by its aerospace and non-Kavach railway businesses. Projected revenues for fiscal year 2026 are between ₹40-41 billion, with its outsourced semiconductor assembly and test (OSAT) and printed circuit board (PCB) operations being key contributors. The core electronics manufacturing services (EMS) segment is expected to grow 35-40% from existing customers and 50% overall. Kaynes' OSAT plant targets 40-50% capacity use by fiscal year 2027, aiming for an 18% profit margin. Its PCB plant is set to generate revenue with a 20% profit margin. This fits with India's EMS market, which is forecast to grow from $65 billion in 2025 to $197.8 billion by 2032, a 17.5% annual growth rate, driven by government incentives.
Quality Power anticipates roughly 50% year-on-year revenue growth, backed by a ₹13 billion order book and high demand for its high-voltage transformers, with capacity expansion in progress.
Granules India Faces US FDA Scrutiny
Although not directly rated by UBS in this update, Granules India is under scrutiny. The US Food and Drug Administration (FDA) issued a warning letter for its Gagillapur facility after an inspection in August 2024, citing violations of good manufacturing practices related to cleaning and contamination. This may affect approvals for new products from this plant, though current manufacturing operations continue. Granules India has started a plan to address these issues and is working with outside consultants. In a separate matter, its US packaging facility in Virginia received a clean report from the FDA following a December 2025 inspection, indicating no immediate action needed.